TipRanks (Tue, 23-Apr 6:25 AM ET)
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
TipRanks (Mon, 22-Apr 7:22 AM ET)
Globe Newswire (Mon, 22-Apr 7:00 AM ET)
Globe Newswire (Wed, 10-Apr 7:00 AM ET)
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
Globe Newswire (Mon, 25-Mar 7:00 AM ET)
Globe Newswire (Fri, 15-Mar 7:00 AM ET)
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
Globe Newswire (Tue, 12-Mar 7:00 AM ET)
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Globe Newswire (Fri, 1-Mar 7:00 AM ET)
Globe Newswire (Wed, 14-Feb 8:30 AM ET)
BioXcel Therapeutics Announces Termination of Proposed Public Offering
Globe Newswire (Tue, 13-Feb 9:00 AM ET)
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Bioxcel Therapeutics trades on the NASDAQ stock market under the symbol BTAI.
As of April 23, 2024, BTAI stock price climbed to $2.97 with 406,010 million shares trading.
BTAI has a beta of 0.86, meaning it tends to be less sensitive to market movements. BTAI has a correlation of 0.00 to the broad based SPY ETF.
BTAI has a market cap of $90.81 million. This is considered a Micro Cap stock.
Last quarter Bioxcel Therapeutics reported $376,000 in Revenue and -$.76 earnings per share. This fell short of revenue expectation by $-334,000 and exceeded earnings estimates by $.15.
In the last 3 years, BTAI stock traded as high as $39.00 and as low as $1.91.
The top ETF exchange traded funds that BTAI belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
BTAI stock has underperformed the market in the last year with a return of -86.6%, while SPY returned +24.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BTAI shares. However, BTAI has outperformed the market in the last 3 month and 2 week periods, returning +13.8% and +12.9%, while SPY returned +4.9% and -2.5%, respectively. This indicates BTAI has been having a stronger performance recently.
BTAI support price is $2.72 and resistance is $2.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTAI stock will trade within this expected range on the day.